Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

BACKGROUND AND OBJECTIVE: Gilteritinib is a novel, highly selective tyrosine kinase inhibitor approved in the USA, Canada, Europe, Brazil, Korea, and Japan for the treatment of FLT3 mutation-positive acute myeloid leukemia. This article describes the clinical pharmacokinetic profile of gilteritinib....

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Pharmacokinet
Autori principali: James, Angela Joubert, Smith, Catherine C., Litzow, Mark, Perl, Alexander E., Altman, Jessica K., Shepard, Dale, Kadokura, Takeshi, Souda, Kinya, Patton, Melanie, Lu, Zheng, Liu, Chaofeng, Moy, Selina, Levis, Mark J., Bahceci, Erkut
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing 2020
Soggetti:
Original Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7550323/
https://ncbi.nlm.nih.gov/pubmed/32304015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-020-00888-w
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi